Amisulpride versus risperidone in the treatment of schizophrenic patients: A double-blind pilot study in Taiwan

Journal of the Formosan Medical Association

Volumn 102, Issue 1, 2003, Pages 30-36

  Hwang, Tzung J ^a   Lee, Shin Min ^b   Sun, Hsiao Ju ^c   Lin, Hsin Nan ^a   Tsai, Shih Jen ^d   Lee, Ying Chiao ^d   Chen, Ying Sheue ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Pali Psychiatric Hospital   (Taiwan)

^c Taoyuan Psychiatric Center   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Amisulpride; Antipsychotic agents; Double blind study; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC SEDATIVE AGENT; RISPERIDONE;

ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; INSOMNIA; LIVER TOXICITY; LONG QT SYNDROME; MALE; MUSCLE RIGIDITY; PARKINSONISM; PILOT STUDY; POSITIVE SYNDROME; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SINUS TACHYCARDIA; STATISTICAL SIGNIFICANCE; TAIWAN; TARDIVE DYSKINESIA; TREMOR; VERTIGO; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; SULPIRIDE; TAIWAN; TREATMENT OUTCOME;

EID: 0038475974     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Perrault G, Depoortere R, Morel E, et al: Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82.
2. Schoemaker H, Clauster Y, Fage D, et al: Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97.
3. Moller HJ, Boyer P, Fleurot O, et al: Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997;132:396-401.
4. Puech A, Fleurot O, Rein W: Amisulpride, an atypical anti-psychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998;98:65-72.
5. Burns T, Bale R: Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res 2001;29: 451-66.
6. Leucht S, Pitschel-Walz G, Engel RR, et al: Amisulpride, an usual "atypical" antipsychotic: a meta-analysis of randomized controlled trial. Am J Psychiatry 2002; 159: 180-90.
7. Loo H, Poirier-Littre MF, Theron M, et al: Amisulpride versus placebo in the medium-term treatment of the negative smptoms of schizophrenia. Br J Psychiatry 1997;170: 18-22.
8. Boyer P, Lecruiber Y, Puech AJ, et al: Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry v 1995;166:68-72.
9. Paillere-Martinot ML, Lecrubier Y, Martinot JL, et al: Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995; 152:130-4.
10. McEvoy JP: Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry 1994;55:18-21.
11. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151-825-35.
12. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-nationa, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-26: discussion 27-33.
13. Carman J, Peuskens J, Vangeneugden A: Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995;10:207-13.
14. Peuskens J, Bech P, Moller HJ, et al: Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88:107-17.
15. American Psychiatry Association: Diagnostic and Statistical Manual Mental Disorders, 4th ed. Washington, DC: American Psychiatry Association, 1994.
16. Cheng JJ, Ho H, Chang CJ, et al: Positive and Neagtive Syndrome Scale (PANSS): establishment and realibilty study of a Mandarin Chinese language version. Clin Psychiatry 1996;10:251-8.
17. Guy W: ECEDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338, Rockville: US Department of Health, Education and Welfare, 1976:217-22.
18. Chourinard G, Ross-Chouinard A, Annable L, et al: The Extra-pyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
19. Chouinard G, Jones B, Remington G, et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 1993;13:25-40.
20. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
21. Conley RR: Risperidone side effects. J Clin Psychiatry 2000;61: 20-3; discussion 4-5.
22. Taylor DM, McAskill R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-32.
23. Wilton LV, Heeley EL. Pickering RM, et al: Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6.
24. Glassman AH, Bigger JT, Jr.: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
25. Agelink MW, Majewski T, Wurthmann C, et al: Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001;21:8-13.
26. Curran MP, Perry CM: Amisulpride: a review of its use in the management od schizophrenia. Drugs 2001;61:2123-50.
27. Coulouvrat C, Dondey-Nouvel L: Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14:209-18.
28. Lin KM, Poland RE: Ethnicity, culture, and psychopharmacology. In Bloom FE, Kupler DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press, 1995: 1907-17.
29. Chang WH, Lin SK, Lane HY, et al: Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 1997;96:599-605.
30. Lane HY, Lin HN, Hwu HG, et al: Haloperidol plasma concentrations in Taiwanese psyciatric patients. J Formos Med Assoc 1995;94:671-8.
31. Pedrosa Gil F, Grohmann R, Ruther E: Asymtomatic bradycardia associated with amisulpride. Pharmacopsychiatry 2001;34: 259-61.
32. Tracqui A, Mutter-Schmidt C, Kintz P, et al: Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 1995; 14:249-8.